Targazyme Announces Appointment of Jim Caggiano as CEO

By StartUp City | Monday, September 14, 2020

Targazyme's clinical-grade fucosyltransferase enzymes and small molecule products (TZ-101 and TZ-102) are off-the-shelf products used during the centralized manufacturing process or the point-of-care to treat therapeutic cells before their infusion into patients.

FREMONT, CA: Targazyme, a late clinical-stage biopharmaceutical company developing novel fucosyltransferase enzyme technologies and products to improve clinical efficacy, safety, and cost of care outcomes for immuno-oncology and stem cell transplantation, announced the appointment of cancer immunotherapy veteran James Caggiano as it’s CEO.

A former US Army Officer, Jim Caggiano, brings nearly 30 years of immuno-oncology, pharmaceutical, and medical device experience at successful companies such as TAP Pharmaceuticals, Allergan, Abbott Laboratories, Valeant, and Dendreon. As President at Valeant, Caggiano led the successful business turnaround of Dendreon, doubled Dendreon's value by selling it to Sanpower Group for $820 million, and became its CEO. Under his leadership, Dendreon earned over $100 million in EBIT in 2018 and 2019.

"We welcome Jim Caggiano to our Targazyme team and look forward to his leadership with advancing our oncology assets to making a life-changing difference for cancer patients and their families worldwide," said Lynnet Koh, Founder and Executive Chairman of Targazyme. "Caggiano brings a track record of delivering major shareholder value through successful execution of sell-side deal transactions and driving major commercial revenue growth. His military leadership skills positions the company for consistently delivering on key milestones on time and on budget."

Targazyme's clinical-grade fucosyltransferase enzymes and small molecule products (TZ-101 and TZ-102) are off-the-shelf products used during the centralized manufacturing process or the point-of-care to treat therapeutic cells before their infusion into patients. Data generated at leading cancer centers show that the fucosylation process of therapeutic cells such as T and NK cells improves their homing to the cancer tumor micro-environment, increases T and NK cell intra-tumor penetration and enhances the cytotoxicity of immune cells for increased cancer tumor killing and better patient outcomes.

"I'm honored to join Targazyme at this exciting and pivotal time in its history," said Caggiano. "I look forward to working with the team here to capitalize on the impressive results of the past and to move these very promising, life-saving therapies forward, ultimately enhancing the lives of cancer patients."

Weekly Brief